Clinical Studies
AbClon's AT101 & CAR-T Therapy Pipeline: A New Era in Hematologic Cancer Treatment
The AT101 CD19 CAR-T therapy, developed using AbClon's proprietary NEST platform, represents a groundbreaking advancement in hematologic cancer treatment. The preclinical data, as shown in the image, demonstrate the superior efficacy of AT101 in eliminating B-cell-derived leukemia cells, surpassing conventional T cell treatments.
How AT101 Stands Out:
Next-Generation Epitope Targeting
Unlike conventional CAR-T therapies that target the FMC63 epitope, AT101 binds to a unique epitope, improving therapeutic precision.
Enhanced Tumor Clearance
Preclinical models show a dramatic reduction in tumor burden, with sustained responses at 28 days.
Lower Side Effects
The innovative binding strategy minimizes off-target toxicity, reducing the risk of cytokine release syndrome (CRS).
Optimized for Relapsed/Refractory Cases
Offers hope for patients who do not respond to traditional CD19 CAR-T therapies.
AbClon's CAR-T Therapy Pipeline: Advancing the Future of Immunotherapy
Beyond AT101, AbClon is actively developing a pipeline of CAR-T therapies to address different cancer types, expanding the impact of next-generation immunotherapy:
AT101 – CD19 CAR-T (Hematologic Malignancies)
Target: CD19
Indication: B-cell leukemia, lymphoma
Status: Clinical stage
Key Advantage: Unique epitope targeting for patients unresponsive to FMC63-based therapies
Learn More About Our Revolutionary Therapies
Discover how TCT Health Technology is bringing cutting-edge treatments to patients